secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001213900-22-009206
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q4 revenue $20.3M (+24% YoY), FY revenue $61.3M (+42%), guides FY22 $80-85M
--------------------------------------------------------------------------------

- Q4 GAAP net income $0.6M ($0.04 diluted EPS); non-GAAP net income $4.0M ($0.22 diluted EPS).
- Gross margin improved to 61% in Q4 from 52.4% a year ago.
- Introduced KPIs: avg revenue per top-20 pharma client $2.5M, 95% penetration, net revenue retention 127%.
- FY22 guidance: revenue $80-85M (+31-39% YoY), gross margin 57-60%.
- Cash and equivalents $84.7M at Dec 31, 2021; cash flow positive from operations $0.7M in FY21.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/0001213900-22-009206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/ea156150-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-009206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer